• 1
    Fantin, V. R., St-Pierre, J., and Leder, P. (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9, 425434.
  • 2
    Ward, P. S. and Thompson, C. B. (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21, 297308.
  • 3
    Pelicano, H., Martin, D. S., Xu, R. H., and Huang, P. (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25, 46334646.
  • 4
    Cairns, R. A., Harris, I. S., and Mak, T. W. (2011) Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 8595.
  • 5
    Granchi, C., Roy, S., Giacomelli, C., Macchia, M., Tuccinardi, T., et al. (2011) Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J. Med. Chem. 54, 1599612.
  • 6
    Semenza, G. L. (2008) Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 60, 591597.
  • 7
    El Mjiyad, N., Caro-Maldonado, A., Ramirez-Peinado, S., and Munoz-Pinedo, C. (2011) Sugar-free approaches to cancer cell killing. Oncogene 30, 253264.
  • 8
    Augoff, K. and Grabowski, K. (2004) [Significance of lactate dehydrogenase measurements in diagnosis of malignancies]. Pol. Merkur. Lekarski. 17, 644647.
  • 9
    von Eyben, F. E. (2001) A systematic review of lactate dehydrogenase isoenzyme 1 and germ cell tumors. Clin. Biochem. 34, 441454.
  • 10
    Kolev, Y., Uetake, H., Takagi, Y., and Sugihara, K. (2008) Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann. Surg. Oncol. 15, 23362344.
  • 11
    Jovanovic, S., Jovanovic, A., and Crawford, R. M. (2007) M-LDH serves as a regulatory subunit of the cytosolic substrate-channelling complex in vivo. J. Mol. Biol. 371, 349361.
  • 12
    Porporato, P. E., Dhup, S., Dadhich, R. K., Copetti, T., and Sonveaux, P. (2011) Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front. Pharmacol. 2, 49.
  • 13
    Sola-Penna, M. (2008) Metabolic regulation by lactate. IUBMB Life 60, 605608.
  • 14
    Brown, J. E., Cook, R. J., Lipton, A., and Coleman, R. E. (2012) Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Clin. Cancer Res. 18, 63486355.
  • 15
    Le, A., Cooper, C. R., Gouw, A. M., Dinavahi, R., Maitra, A., et al. (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. USA 107, 20372042.
  • 16
    Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Gatter, K. C., and Harris, A. L. (2006) Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway—a report of the Tumour Angiogenesis Research Group. J. Clin. Oncol. 24, 43014308.
  • 17
    Shim, H., Dolde, C., Lewis, B. C., Wu, C. S., Dang, G., et al. (1997) c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA 94, 66586663.
  • 18
    Semenza, G. L., Roth, P. H., Fang, H. M., and Wang, G. L. (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269, 2375723763.
  • 19
    Dang, C. V. (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19, 111.
  • 20
    Dang, C. V. (2004) The interplay between MYC and HIF in the Warburg effect. Ernst Schering Found. Symp. Proc 4, 3553.
  • 21
    Zhao, Y., Liu, H., Riker, A. I., Fodstad, O., Ledoux, S. P., et al. (2011) Emerging metabolic targets in cancer therapy. Front. Biosci. 16, 18441860.
  • 22
    Dang, C. V., Le, A., and Gao, P. (2009) MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 15, 64796483.
  • 23
    Yeung, S. J., Pan, J., and Lee, M. H. (2008) Roles of p53, MYC and HIF-1 in regulating glycolysis—the seventh hallmark of cancer. Cell. Mol. Life Sci. 65, 39813999.
  • 24
    Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707712.
  • 25
    Zhao, Y. H., Zhou, M., Liu, H., Ding, Y., Khong, H. T., et al. (2009) Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene 28, 36893701.
  • 26
    Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., et al. (2011) Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732744.
  • 27
    Luo, W. and Semenza, G. L. (2011) Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2, 551556.
  • 28
    Yang, W., Zheng, Y., Xia, Y., Ji, H., Chen, X., et al. (2012) ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell. Biol. 14, 12951304.
  • 29
    Langhammer, S., Najjar, M., Hess-Stumpp, H., and Thierauch, K. H. (2011) LDH-A influences hypoxia-inducible factor 1alpha (HIF1 alpha) and is critical for growth of HT29 colon carcinoma cells in vivo. Target Oncol. 6, 155162.
  • 30
    Shim, H., Dolde, C., Lewis, B. C., Wu, C. S., Dang, G., et al. (1997) c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA 94, 66586663.
  • 31
    Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., et al. (2013) AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell. Metab. 17, 113124.
  • 32
    Roschewski, M., Weniger, M., Kurdziel, K., Pittaluga, S., Tian, X., et al. (2010) FDG-PET as a marker of tumor proliferation compared to gene-expression proliferation scores, MIB1%, and LDH in untreated mantle cell lymphoma (MCL). Blood 116, 12751276.
  • 33
    Xie, H., Valera, V. A., Merino, M. J., Amato, A. M., Signoretti, S., et al. (2009) LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol. Cancer Ther. 8, 626635.
  • 34
    Ashrafian, H., O'Flaherty, L., Adam, J., Steeples, V., Chung, Y. L., East, P., et al. (2010) Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis. Cancer Res 70, 91539165.
  • 35
    Alvarez-Lorenzo, C., Sosnik, A., and Concheiro, A. (2011) PEO-PPO block copolymers for passive micellar targeting and overcoming multidrug resistance in cancer therapy. Curr. Drug Targets 12, 11121130.
  • 36
    Rong, Y., Wu, W., Ni, X., Kuang, T., Jin, D., et al. (2013) Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol. 34, 15231530.
  • 37
    Yao, F., Zhao, T., Zhong, C., Zhu, J., and Zhao, H. (2013) LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol. 34, 2531.
  • 38
    Sheng, S. L., Liu, J. J., Dai, Y. H., Sun, X. G., Xiong, X. P., and Huang, G. (2012) Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma. Febs J. 279, 38983910.
  • 39
    Colgan, S. M., Mukherjee, S., and Major, P. (2007) Hypoxia-induced lactate dehydrogenase expression and tumor angiogenesis. Clin. Colorectal Cancer 6, 442446.
  • 40
    Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Gatter, K. C., Trarbach, T., et al. (2011) Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin. Cancer Res. 17, 48924900.
  • 41
    Suh, S. Y. and Ahn, H. Y. (2007) Lactate dehydrogenase as a prognostic factor for survival time of terminally ill cancer patients: a preliminary study. Eur. J Cancer 43, 10511059.
  • 42
    Armstrong, A. J., George, D. J., and Halabi, S. (2012) Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J. Clin. Oncol. 30, 34023407.
  • 43
    Yao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., et al. (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J. Clin. Oncol. 26, 43114318.
  • 44
    Azuma, M., Shi, M. M., Jacques, C. J., Barrett, C., Danenberg, K. D., et al. (2006) Tumor VEGFA gene expression is associated with serum lactate dehydrogenase (LDH) levels and intratumoral mRNA expression of genes involved in glycolysis in patients with metastatic colorectal cancer (mCRC). J. Clin. Oncol. 24, 153S.
  • 45
    Azuma, M., Shi, M., Danenberg, K. D., Gardner, H., Barrett, C., et al. (2007) Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics 8, 17051713.
  • 46
    Hecht, J. R., Trarbach, T., Jaeger, E., Hainsworth, J., Wolff, R., et al. (2005) A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J. Clin. Oncol. 23, 2S.
  • 47
    Guo, J., Higashi, K., Yokota, H., Nagao, Y., Ueda, Y., et al. (2004) In vitro proton magnetic resonance spectroscopic lactate and choline measurements, 18F-FDG uptake, and prognosis in patients with lung adenocarcinoma. J. Nucl. Med. 45, 13341339.
  • 48
    Zhou, M., Zhao, Y., Ding, Y., Liu, H., Liu, Z., et al. (2010) Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol. Cancer 9, 33.
  • 49
    Oermann, E. K., Wu, J., Guan, K. L., and Xiong, Y. (2012) Alterations of metabolic genes and metabolites in cancer. Semin. Cell. Dev. Biol. 23, 370380.
  • 50
    Zhang, Y., Zhang,X., Wang, X., Gan, L., Yu, G., et al. (2012) Inhibition of LDH-A by lentivirus-mediated small interfering RNA suppresses intestinal-type gastric cancer tumorigenicity through the downregulation of Oct4. Cancer Lett. 321, 4554.
  • 51
    Granchi, C., Bertini, S., Macchia, M., and Minutolo, F. (2010) Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr. Med. Chem. 17, 672697.